相关实验视频

Updated: May 10, 2025

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

乙酸通过AKT/NLRP3信号通路保护脏缺血-再和热

Liu Xin¹, Ning Kanghao², Li Jiacheng¹

¹The First Affiliated Hospital of Hebei North University, Hebei Province, China.

|April 22, 2025

概括

乙酸 (SA) 通过抑制热致死,保护功能免受缺血-再损伤 (RIRI) 的影响. 这项研究揭示了SA的治疗潜力,通过向AKT/NLRP3信号通路来减少损伤.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

缺血-再损伤 (RIRI) 是急性损伤的主要原因.
酸 (SA) 显示对RIRI具有潜在的治疗益处,但其机制尚未完全理解.

研究的目的:

在小鼠RIRI模型中评估SA的疗效.
阐明SA对RIRI的保护作用的潜在机制.

主要方法:

鼠标RIRI模型建立和SA处理.
生物信息分析以确定关键途径.
在体外和体内验证SA的作用机制.

主要成果:

在RIRI小鼠中,SA表明对功能有保护作用.
在RIRI中,生物信息分析确定了pyroptosis通路的激活.
氨基酸的使用降低了热致死标记物 (GSDMD,NLRP3,IL-1β) 并抑制了AKT/NLRP3信号通路.

结论:

通过通过AKT/NLRP3通路抑制热致死,SA在RIRI中减轻损伤.
SA代表了RIRI的一个有前途的治疗剂,提供对功能衰竭的保护.

关键词:

在 AKT/NLRP3 信号系统中.缺血-再输液损伤的脏缺血.热致灭症是什么?甲酸是一种酸.

更多相关视频

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...